KDOQI对2018 KDIGO丙型肝炎指南的美国解读
NKF-KDOQI对2018 KDIGO丙型肝炎指南进行深度解读,重点关注直接抗病毒药物(DAA)时代下慢性肾脏病、透析及肾移植患者的HCV治疗。KDIGO工作组因DAA可及性对指南第2章和第4章做了重大更新,解读旨在为肾内科医生提供实用指导,并提及HCV感染供肾移植的新机会。
要点
- DAA药物使HCV治愈率常规超过95%,指南第2、4章据此重大更新。
- 解读面向CKD、透析及肾移植患者的HCV管理提供实践指导。
- DAA安全性高效性支持HCV感染供肾移植的新应用。
核心结论
- DAA药物使HCV治愈率常规超过95%,KDIGO据此更新指南第2章和第4章。
- 安全高效的DAA为HCV感染供肾移植创造了新机会,并可能改善长期结局。
研究设计与样本
- NKF-KDOQI对2018 KDIGO HCV指南的评论性解读,非系统综述或原始研究。
主要发现
- KDIGO工作组因DAA可及性对指南第2章和第4章做了重大更新。
- DAA药物治愈率常规超过95%。
临床怎么用
- 肾内科医生应依据更新指南管理CKD、透析及肾移植患者的HCV感染。
- 可考虑使用HCV感染供肾进行移植,并治疗受者的HCV感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The first KDIGO (Kidney Disease: Improving Global Outcomes) guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection was published in 2008. The ensuing decade bore witness to remarkable advances in the treatment of HCV infection following the approval of direct-acting antiviral (DAA) agents that deliver cure rates routinely >95%. In this context, the KDIGO organization correctly recognized the need for an updated HCV guideline that would be relevant to the treatment of HCV-infected patients with kidney disease in the DAA era. The current NKF-KDOQI (National Kidney Foundation-Kidney Disease Outcomes Quality Initiative) commentary provides an in-depth review and perspective on the 2018 KDIGO guideline. Of note, the KDIGO work group made significant updates to guideline chapters 2 and 4 as a direct result of the availability of DAAs. The intent of this commentary is to provide useful interpretation for nephrologists and other practitioners caring for HCV-infected patients with chronic kidney disease, including dialysis patients and kidney transplant recipients. The availability of DAA agents that are safe and highly effective has created new opportunities, such as the transplantation of kidneys from HCV-infected kidney donors. The ability to treat HCV infection in patients with kidney disease will have a significant impact on the care of our patients and should favorably influence long-term outcomes as well.
引用
- Roth D, Bloom RD, Molnar MZ, et al. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. Am J Kidney Dis. 2020. PMID: 32279907. doi:10.1053/j.ajkd.2019.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。